Much of the focus on the impact of GLP-1 receptor agonists (and combination drugs with components that target other receptors such as gastric inhibitory polypeptide collectively termed GLP-1s in this article) to date has been on their potential to improve long-term health outcomes for people with type 2 diabetes, obesity, and related cardiovascular diseases
4 Robust generic competition for these products will be crucial for lowering prices in the coming years
In 2015, Novo Nordisk changed its pricing strategy in advance of launching Tresiba, its next generation basal insulin (also known as long-acting insulin)
Nevertheless, the process of developing unimolecular agonists is challenging, entailing a precise understanding of the optimized ratios of each contributing molecular entity and potential complexity in interpreting unanticipated side effects
Endometrial stem/progenitor cells and their role in the pathogenesis of endometriosis
DAC Contrast CJC with DAC, a version I dont use at all